Two Sigma Securities, LLC Crispr Therapeutics Ag Call Options Transaction History

Two Sigma Securities, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$51.17 - $68.18 $337,722 - $449,988	6,600 Added 23.49%	34,700 $1.87 Million
Q1 2024 May 15, 2024	SELL	$60.67 - $89.12 $1.43 Million - $2.09 Million	-23,500 Reduced 45.54%	28,100 $1.92 Million
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $1.04 Million - $1.95 Million	27,000 Added 109.76%	51,600 $3.23 Million
Q3 2023 Nov 14, 2023	BUY	$45.39 - $59.0 $149,787 - $194,700	3,300 Added 15.49%	24,600 $1.12 Million
Q2 2023 Aug 14, 2023	BUY	$43.47 - $67.77 $925,911 - $1.44 Million	21,300 New	21,300 $1.2 Million
Q4 2022 Feb 14, 2023	SELL	$39.19 - $65.67 $356,629 - $597,597	-9,100 Reduced 38.4%	14,600 $593,000
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $1.15 Million - $1.58 Million	18,900 Added 393.75%	23,700 $1.55 Million
Q2 2022 Aug 15, 2022	SELL	$43.23 - $73.83 $129,689 - $221,490	-3,000 Reduced 38.46%	4,800 $292,000
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $414,882 - $618,072	7,800 New	7,800 $490,000
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $363,660 - $516,911	-3,300 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$100.84 - $161.89 $332,772 - $534,237	3,300 New	3,300 $534,000

499

56.8M

1.7M

1.8M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.05B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Securities, LLC with notifications on news.